Vinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.xVinaora Nivo Slider 3.x

SUMMARY

An accurate enzyme replacement arises as an early nutritional intervention able to provide better nutritional status and patients’ welfare from early stages avoiding complications associated to the development of the disease. By means of our innovative and portable ICT tool we will improve the socio-economic impact of the disease, promoting healthy lifestyle, intertwining patient empowerment, education and training with self-management and prevention of secondary CF-complications. The multidisciplinary and complementary approach of this co-developed integrative PROJECT guarantees the patient’s adherence to the treatment and the best outcome of the nutritional intervention mainly in childhood. The beneficiaries of the application comprise patients, caregivers, families and health professionals as well as health monitoring authorities. MyCyFAPP is tailored designed and will be clinically validated for CF self-management and monitoring becoming a competitive market product in Europe. This APP will have a key role as decision support system, boosting the growth and competitiveness of the participating SMEs in Europe, which will ensure the market uptake and the MyCyFAPP distribution for the benefit of the patient.

OBJECTIVES

It is to get to a scenario in which self-management of enzyme replacement in the European Cystic Fibrosis (CF) patients by means of a mobile application (APP) is progressively achieved and successfully implemented. The co-developed APP is aimed at a personalised and accurate control and monitoring of the disease thanks to the interaction between health professionals and patients.

EXPECTED OUTCOMES

1. Health and nutritional status improvement through a precise enzyme dosage.
2. Improved Quality of life both for patients and their families.
3. Economic savings both for the health system and for the patients’ families.